Deerfield Management

Every Cure co-founder David Fajgenbaum, MD, MBA, MSc, was a third-year medical student with Castleman disease (CD). After exhausting all available treatment options, David launched an initiative to save his life and the lives of other patients with CD, discovering an overactive pathway in his blood and using a 25-year-old drug originally used for another purpose to block that pathway. Due to this repurposed drug, David has been in remission for over a decade and is now the author of a bestselling memoir describing his experience ("Chasing My Cure: A Doctor’s Race to Turn Hope Into Action”). Today, Every Cure uses AI to find the most promising opportunities for repurposing drugs across all diseases, having advanced 28 repurposed drugs e to date. The company was recently named as a winner of the inaugural Cure. Xchange Challenge: Health AI for Good. As winners of the challenge, Every Cure and four other AI-focused healthcare startups were recognized for their potential to revolutionize #healthcare and improve #patientoutcomes. In partnership with MIT Solve, Cure created the Xchange Challenge to incubate transformative healthcare innovations. Learn more about Every Cure here: https://bit.ly/3WoRWwg *Cure is an affiliate of #DeerfieldManagement.

This #DisabilityPrideMonth, we are proud to partner with Achilles International to help transform the lives of people with disabilities through athletic programs and social connection. Achilles International is a 2024 grantee of the #DeerfieldFoundation and funding supports the Achilles Kids’ wheelchair racing training program, which offers free and inclusive practices at CUNY Queens College Track every week through July. Launched in 2023, the initiative aims to expand adaptive wheelchair racing access for children in New York City, while fostering a community where young people with disabilities can exercise alongside peers and build mentorships with adults with disabilities. Learn more: https://bit.ly/4bNgH9C ***The Deerfield Foundation, #DeerfieldManagement’s philanthropic affiliate, is partnering with Achilles International and other #nonprofits addressing #globalhealth challenges to improve health disparities across the world. #DisabilityPrideMonth #AccessibilityMatters #Inclusion

Last month #DeerfieldManagement hosted its 2024 Corporate Day, where employees met and mentored young adults from community institutions Covenant House International and The Family Center. Participants gathered for a full day of activities, including a panel discussion exploring Journeys in Healthcare where panelists spoke about their personal experiences navigating their careers; HealthTank, an interactive activity where young adults engaged in a simulation of private healthcare investment modeled after ABC’s "Shark Tank"; a hands-on DNA extraction exercise with Deerfield Discovery and Development (3DC); a strawberry-centric biochemistry experiment with Deerfield portfolio company Pairwise and dedicated small-group mentorship sessions. Thank you to our partners for helping us make a lasting impact on these scholars! *All individuals depicted have consented to being included in photos.

Deerfield’s partnership with Horizon Blue Cross Blue Shield of New Jersey is focused on empowering independent physicians to remain competitive in today’s environment. Read more:

We are thrilled to share highlights from our recent AML Summit, where healthcare experts, leaders, and partners gathered at the Cure innovation campus to push the boundaries of acute myeloid leukemia (AML) research. Congratulations once again to our 2023-2024 recipients of the ASH Peter Steelman Scholar Award, Emily Heikamp, MD PhD, MSc, and Sascha Haubner, M.D. Heartfelt thanks to all participants and guest speakers for your passion and dedication to advancing the fight against AML. o Ross Levine, M.D., Chair of the AML Summit o Scott Armstrong MD, PhD o Kamal Menghrajani, M.D., M.S. o Manuel Aivado, M.D., Ph.D. o Julian Adams, Ph.D. o Jeffrey Spear, LLP Together, we are making strides in transforming the future of healthcare. *The ASH Peter Steelman Scholar Award is presented by #DeerfieldManagement and Deerfield Foundation in partnership with American Society of Hematology. Named in honor of former Deerfield Management Partner Peter Steelman, the award commemorates his lasting impact as a dedicated team member and a compassionate individual who embraced everyone with acceptance and kindness.

This week, David Greenwald, Ph.D., Vice President of Business Development at #DeerfieldManagement, will speak at the FT Live - Funding Biopharma Innovation event, which will take place virtually and in person at the Cure Innovation Labs. David will join Financial Times Correspondent Oliver Barnes for a fireside chat to share an investor’s perspective on the drug development pipeline. The conversation will cover private equity trends in pharma and biotech, the changing biotech funding landscape, and ways startups can stand out from the competition. Learn more and register for free to tune in: https://bit.ly/4cdIlOl

Deepecho is a health tech and AI-focused company working to democratize access to fetal ultrasound. Their technology helps healthcare providers diagnose, prevent, and predict prenatal complications. As a winner of the Cure. Xchange Challenge, Deepecho and four other AI-focused healthcare startups were recognized for their potential to revolutionize #healthcare and improve #patientoutcomes. In partnership with MIT Solve, Cure created the Xchange Challenge to incubate transformative healthcare innovations. Learn more about Deepecho here: https://www.deepecho.io/ *Cure is an affiliate of #DeerfieldManagement.

“This award has great significance to me not only for the recognition, but also for the financial support, which will be essential for my future efforts to further optimize CAR therapies in acute myeloid leukemia.” 2024 recipient of the ASH Peter Steelman Scholar Award, Sascha Haubner, M.D., will be honored at today’s AML Summit, presented by #DeerfieldManagement and the Deerfield Foundation in partnership with the American Society of Hematology. Learn more: https://bit.ly/3UtrXBE

Yesterday #DeerfieldManagement announced an $81M Series B investment into Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of invasive fungal infections (IFIs). This will support the progress of the company’s clinical-stage candidate through a multiple-ascending dose study. “Fungal infections are a growing medical concern globally, and we have an opportunity with [Elion’s] therapeutic candidate to address millions of disease cases and preventable deaths that occur every year,” said James Flynn, Managing Partner at Deerfield. Learn more: https://prn.to/3KQjZOB

As the 2023 recipient of the ASH Peter Steelman Scholar Award, Emily Heikamp, MD PhD, MSc, remains committed to making a meaningful impact on the advancement of research for this cancer of the bone marrow and blood. We are proud to recognize the 2023-2024 ASH Peter Steelman Scholar Award recipients at the upcoming second annual AML Summit, presented by #DeerfieldManagement and the Deerfield Foundation in partnership with the American Society of Hematology. Learn more: https://bit.ly/3UtrXBE